UMIN-CTR Clinical Trial

Recruitment status Preinitiation
Unique ID issued by UMIN UMIN000023517
Receipt No. R000027090
Official scientific title of the study A study on the efficacy and safety of cyclodextrin intrathecal long-term administration for Niemann-Pick disease type C
Date of disclosure of the study information 2016/10/01
Last modified on 2016/08/06 (Ver. 1)

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Official scientific title of the study A study on the efficacy and safety of cyclodextrin intrathecal long-term administration for Niemann-Pick disease type C
Title of the study (Brief title) IT-HPBCD therapy for NPC (Long-term)
Region
Japan

Condition
Condition Niemann-Pick disease type C
Classification by specialty
Endocrinology and Metabolism Neurology Pediatrics
Classification by malignancy Others
Genomic information NO

Objectives
Narrative objectives1 We use IT-HPBCD therapy for NPC patients with Miglustat resistance.
Basic objectives2 Safety,Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase

Assessment
Primary outcomes NPC-ADL score after 12th administration of HPBCD
Key secondary outcomes

Base
Study type Interventional

Study design
Basic design Single arm
Randomization Non-randomized
Randomization unit
Blinding Open -no one is blinded
Control Uncontrolled
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms 1
Purpose of intervention Treatment
Type of intervention
Medicine
Interventions/Control_1 2-hydroxypropyl-beta-cyclodextrin (HPBCD) 20mg/kg/dose, every 3-4 weeks, for three years
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
4 years-old <=
Age-upper limit
6 years-old >
Gender Male and Female
Key inclusion criteria 1)Genetically proven NPC
2)Neurological involvement
3)Miglustat resistance
Key exclusion criteria 1)CNS or systemic infection
2)Without neurological involvement
Target sample size 1

Research contact person
Name of lead principal investigator Takafumi Sakakibara
Organization Nara Medical University
Division name Department of Pediatrics
Address 840 Shijo-Cho, Kashihara, Nara, Japan
TEL 0744-22-3051
Email kumasan@naramed-u.ac.jp

Public contact
Name of contact person Takafumi Sakakibara
Organization Nara Medical University
Division name Department of Pediatrics
Address 840 Shijo-Cho, Kashihara, Nara, Japan
TEL 0744-22-3051
Homepage URL
Email kumasan@naramed-u.ac.jp

Sponsor
Institute Nara Medical University
Institute
Department

Funding Source
Organization Nara Medical University
Organization
Division
Category of Funding Organization Other
Nationality of Funding Organization

Other related organizations
Co-sponsor
Name of secondary funder(s)

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions

Other administrative information
Date of disclosure of the study information
2016 Year 10 Month 01 Day

Progress
Recruitment status Preinitiation
Date of protocol fixation
2016 Year 10 Month 01 Day
Anticipated trial start date
2016 Year 10 Month 01 Day
Last follow-up date
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Related information
URL releasing protocol
Publication of results Unpublished
URL releasing results
Results
Other related information

Management information
Registered date
2016 Year 08 Month 06 Day
Last modified on
2016 Year 08 Month 06 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000027090